GlassScriptPhysician profile
Samantha Avoke
NPI 1942662499
$1,141.77
in general payments reported to CMS, 2019-2025
21 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.97 · 2020: $115 · 2021: $60.60 · 2022: $196 · 2023: $326 · 2024: $301 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $162.25 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $149.17 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $137.15 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $100.34 | 2022-2025 | |
| Lilly USA, LLC | $91.02 | 2022-2023 | Mounjaro |
| Astellas Pharma US INC | $66.16 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $56.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $44.31 | 2020 | |
| Ibsa Pharma INC. | $37.16 | 2024 | Licart, Tirosint, Flector |
| Bayer Healthcare Pharmaceuticals INC. | $36.50 | 2023 | |
| Exact Sciences Corporation | $33.83 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $30.42 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.60 | 2022 | |
| Corcept Therapeutics | $19.64 | 2025 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.11 | 2022 | |
| Amgen INC. | $15.71 | 2020 | |
| Cequr Corporation | $14.99 | 2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $13.70 | 2022 | |
| Currax Pharmaceuticals LLC | $13.67 | 2025 | Contrave |
| Teva Pharmaceuticals USA, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Avoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.